Biomarker Opportunity Eysz focuses on biomarker-based tools for neurological disorders, starting with epilepsy, ADHD, and mood. This presents opportunities to partner with hospitals, clinics, and research centers seeking objective data to improve diagnosis and personalized care.

AI EyeMovement Company has a history of developing AI-driven software analyzing passive eye movements from eye-tracking systems to capture seizure burden and cognitive side effects, signaling potential for integration with neuro-monitoring platforms and wearable eye-tracking devices.

Clinical Data Stack Tech stack includes AWS, PWA, and analytics tools, indicating readiness for cloud-based clinical data solutions, secure data pipelines, and scalable clinician-facing apps suitable for health systems and telehealth partners.

Strategic Funding Past funding from Hundley Foundation and Reg CF signals active investor interest in neurodigital health, suggesting messaging opportunities around social impact, patient outcomes, and growth potential to similar impact-focused investors and grant programs.

Growth Readiness Revenue range and small team size imply an early-stage but scalable product with potential for partnerships with larger medical device manufacturers, EHR vendors, and specialty clinics seeking to enhance diagnostic accuracy and personalized treatment pathways.